Oura Receives $75 Million Series D Investment, Partners With Dexcom to Expand Metabolic Health Offerings

  • 📰 wwd
  • ⏱ Reading Time:
  • 44 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 21%
  • Publisher: 68%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

Oura, known for its health tracking ring, has received a $75 million series D and inked a partnership with Dexcom to expand its metabolic health offerings.

from Dexcom, a continuous glucose monitoring company, bringing Oura’s total valuation to more than $5 billion. The brand has sold more than 2.5 million rings to date, tripled its member base in the last three years and is expected to reach $500 million in sales this year.“Ninety-seven percent of Oura members have expressed interest in understanding how the food they eat impacts their health,” said Oura chief executive officer Tom Hale in a statement.

For Dexcom, this partnership will bring continuous glucose monitoring to a wider array of customers. Dexcom also recently launched Stelo, the first FDA-approved, over-the-counter glucose biosensor. Previously, prescriptions were required for continuous glucose monitors. “Partnering with Oura gives us the opportunity to redefine the category again, integrating data from Dexcom glucose biosensors with the continuous insights and metrics measured by Oura Ring,” said Matt Dolan, executive vice president of strategy and corporate development at Dexcom, in a statement. “This powerful combination will attract new shared customers who want to better understand the link between activity, sleep, nutrition and their glucose.

WWD and Women's Wear Daily are part of Penske Media Corporation. © 2024 Fairchild Publishing, LLC. All Rights Reserved.

 

コメントありがとうございます。コメントは審査後に公開されます。
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 24. in JP

日本 最新ニュース, 日本 見出し